Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.62 |
| ▸ | CTSL | P07711 | 9/20 | 0.61 |
| ▸ | CTSS | P25774 | 8/20 | 0.61 |
| ▸ | CTSB | P07858 | 4/20 | 0.61 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.57 |
| ▸ | CAPNS1 | P04632 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8406499 | 1.00 | CTSK (0.62) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL7514109 | 1.00 | CTSK (0.62) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL7525753 | 0.98 | CTSK (0.61) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL7515987 | 0.95 | CTSK (0.61) | CTSKCTSLCTSSCTSB | |
| SCHEMBL8811434 | 0.92 | CAPN1 (0.52) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL8811449 | 0.92 | CAPN1 (0.52) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL3592461 | 0.91 | CTSK (0.64) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL7514113 | 0.91 | CTSK (0.59) | CTSKCTSLCTSSCTSB | |
| SCHEMBL4621195 | 0.89 | CTSK (0.62) | CTSKCTSLCTSSCTSBCAPN1 | |
| SCHEMBL4622199 | 0.89 | CTSK (0.62) | CTSKCTSLCTSSCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642591-B2 | Composition containing amidine derivatives or carboxamide derivatives and steroids, as a medicament | IPSEN PHARMA S.A.S. (FR) | 2014-02-04 | — | — | US | disclosed |
| EP-1954288-B1 | AMIDINE DERIVATIVES AND THEIR USES AS MEDICINE | IPSEN PHARMA (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-7659266-B2 | Amidine derivatives and their applications as a medicament | S.C.R.A.S. (FR) | 2010-02-09 | — | — | US | disclosed |
| US-20090149430-A1 | COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2009-06-11 | — | — | US | disclosed |
| US-20090018120-A1 | AMIDINE DERIVATIVES AND THEIR APPLICATIONS AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2009-01-15 | — | — | US | disclosed |
| EP-1954288-A1 | AMIDINE DERIVATIVES AND THEIR USES AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007045761-A1 | AMIDINE DERIVATIVES AND THEIR USES AS MEDICINE | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149430-A1 | COMPOSITION CONTAINING AMIDINE DERIVATIVES OR CARBOXAMIDE DERIVATIVES AND STEROIDS, AS A MEDICAMENT | MC2R, CYP11B2, NR3C2 | CTSK 1860/4885CTSL 2116/4885CTSS 1982/4885 |
| US-20090018120-A1 | AMIDINE DERIVATIVES AND THEIR APPLICATIONS AS A MEDICAMENT | CAPN2, CAPN9, CAPN1 | CTSK 148/4885CTSL 154/4885CTSS 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.